Finch’s C. diff drug cleared of FDA hold, but loose ends leave timing for phase 3 restart unclearnews2022-04-29T12:46:13+00:00April 29th, 2022|FierceBiotech|
AstraZeneca kicks off work on 1,500-person R&D center in Kendall Square news2022-04-29T08:54:48+00:00April 29th, 2022|FierceBiotech|
‘Serious missteps’: All Blue makes case for $773M Zymeworks buyout in wake of flagging stocknews2022-04-29T07:54:15+00:00April 29th, 2022|FierceBiotech|
Chutes & Ladders—Merck loses another top exec, this time to Modernanews2022-04-28T21:33:40+00:00April 28th, 2022|FierceBiotech|
Researchers take heart from mRNA’s potential to boost recovery from cardiac attacknews2022-04-28T19:29:36+00:00April 28th, 2022|FierceBiotech|
With the makings of a hub, NYC primed to be life sciences leadernews2022-04-28T16:48:03+00:00April 28th, 2022|FierceBiotech|
Sanofi moves patients out of Ukraine warzone in ‘Herculean effort’ to preserve MS trialsnews2022-04-28T16:46:05+00:00April 28th, 2022|FierceBiotech|
UPDATE: Sio Gene Therapies warns of ‘significant’ layoffs after ditching final two assetsnews2022-04-28T14:21:04+00:00April 28th, 2022|FierceBiotech|
UPDATE: Sio Gene Therapies warns of ‘significant’ layoffs after ditching final 2 assetsnews2022-04-28T14:21:04+00:00April 28th, 2022|FierceBiotech|
Pfizer’s phase 3 DMD gene therapy test resumes after FDA hold, but decision on advanced patients still pendingnews2022-04-28T12:55:20+00:00April 28th, 2022|FierceBiotech|
